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surgical trials was a strong risk factor for nonpublication (odds ratio = 4.18,
95% CI: 1.45–12.06; P = 0.008).
Conclusions: Discontinuation and nonpublication rates were substantial in
surgical RCTs and trial discontinuation was strongly associated with non-
publication. These findings need to be taken into account when interpreting
surgical literature. Surgical trialists should consider feasibility studies before
embarking on full-scale trials.
Keywords: discontinuation, publication, randomized controlled trial, recruit-
ment
(Ann Surg 2014;00:1–6)
R andomized controlled trials (RCTs) can provide high-level ev-idence about safety and efficacy of interventions. Conducting
RCTs involving surgical interventions presents challenges distinct
from RCTs investigating pharmacological interventions. Examples
are standardization of operative and perioperative interventions, sur-
geon and team experience, blinding of study personnel, and partici-
pants and recruitment (eg, due to patient preference).1–3
Trials may be discontinued earlier than planned for various
reasons, including compelling evidence of treatment benefit or harm,
futility, slow recruitment, commercial reasons, or the emergence of
new evidence from other trials that negates the need for another
study.4,5 When there is no early evidence of harm or irrefutable ben-
efit, trial discontinuation has a significant scientific, ethical, and eco-
nomic impact. The involvement of steering committees and Data
and Safety Monitoring Boards with members independent of the
sponsor is of utmost importance when deciding to stop a trial early.
Moreover, reasons for early trial termination should be transpar-
ently communicated. To the best of our knowledge, discontinuation
of surgical trials and the associated risk factors have not yet been
investigated.
We determined the prevalence of, and reasons for, discontinu-
ation of surgical trials. We further explored differences in the preva-
lence of discontinuation between medical and surgical trials and risk
factors for nonpublication of surgical trials.
METHODS
Included Studies
We identified RCTs conducted in adult patients from a large
empirical study investigating trial protocols approved between 2000
and 2003 by 6 research ethics committees (RECs) in Canada,
Germany, and Switzerland.6 Details of the study design have been
previously described.7 For the current analysis, we used the follow-
ing prespecified definitions: all RCTs conducted among adult patients
in clinical areas with surgical or perioperative activities were classi-
fied as “surgical.” These included anesthesiology, general surgery,
vascular surgery, transplantation, orthopedics traumatology, cardio-
thoracic surgery, cardiovascular surgery, neurosurgery, urology, plas-
tic surgery, maxillofacial surgery, ear-nose-throat surgery, obstetrics/
gynecology, ophthalmology, and dentistry. All RCTs conducted
among adult patients in clinical areas primarily relying on nonsur-
gical activities were classified as “medical”. Examples are cardiol-
ogy, gastroenterology, infectious diseases, neurology, and oncology
(for full details see Supplemental Digital Content Table 1, available at
http://links.lww.com/SLA/A585). In both groups, study interventions
were classified as noninvasive (eg, disinfection with antiseptic agent
in a “surgical” trial, antihypertensive medication in a “medical” trial)
or invasive (eg, colon resection in a “surgical” trial, colonoscopy in a
“medical” trial).
Data Extraction
We used a web-based password-protected database for data
extraction (http://www.squiekero.org/). Collaborators trained in trial
methodology signed confidentiality declarations for the participat-
ing RECs; completed a calibration process; and then extracted study
characteristics such as information concerning the study population,
intervention, control, sample size, and funding from the included
RCT protocols. The first 310 (30%) trial protocols were extracted
independently and in duplicate; disagreements were resolved by dis-
cussion. For pragmatic reasons, the remaining protocols were ex-
tracted by a single investigator with regular agreement checks using
double data extraction We determined completion status and publi-
cation history of RCTs as of April 2013 by using information from
REC files if available, by conducting comprehensive searches of elec-
tronic databases for corresponding publications, and directly contact-
ing trialists as described previously.7 Two investigators independently
assessed whether the publications identified by electronic searches
matched the corresponding protocol.7
An RCT was considered as discontinued if the investigators
indicated discontinuation with a reason in the correspondence with
the REC, in a journal publication, or their response to our survey.
If we could not elucidate the reason for trial discontinuation or if
poor participant recruitment was mentioned, we used a prespecified
cutoff of less than 90% of achieved target sample size to determine
discontinuation.7 In the rare case that several reasons per study were
indicated, the primary reason reported was used. Results were re-
garded as not published at all if the REC files, the contacted inves-
tigators, and the electronic database search yielded no evidence that
the data were published in any format. In addition, it was evaluated
whether results were published as full journal article. We defined
sponsorship depending on who took responsibility for the trial: We
considered protocols as industry sponsored, if they were written by
industry employees, prominently displayed a company logo or name,
reported full funding by the industry without any indication that the
trial was investigator sponsored, or mentioned a specific policy with
respect to data ownership and publication rights suggesting sponsor-
ship by the industry.
In surgical trials, we explored whether authors reported a pri-
mary outcome for harm. One investigator coded this information
based on the previously extracted information, and any ambiguity
was discussed with a second investigator. The rationale to include
this variable is the fact that adverse events may be rare or occur late
in the sequence of the trial, thus adequately powered studies reach-
ing the targeted sample size and the defined follow-up are of utmost
importance.
Statistical Analysis
We used descriptive statistics to report the prevalence of and
reasons for discontinuation. We compared features of surgical and
medical RCTs using theχ 2 test or the Fisher exact test, as appropriate,
and calculated a risk difference and its 95% confidence interval (CI).
We excluded trials that never started (according to REC files or our
investigator survey) or that were still ongoing when calculating rates
of trial completion and publication status.
We built multivariable logistic regression models to identify
predictors for discontinuation due to slow recruitment. Because there
are well-justified reasons for trial discontinuation, we did not ex-
plore reasons for discontinuation overall, but for discontinuation due
to slow recruitment only, which we estimated to be an inappropri-
ate reason for early termination. To avoid overfitting, the number
of included covariates was limited to one per 10 events/nonevents,
whichever was the smaller number in all multivariable regression
analyses.8 Covariates were chosen a priori to explore the following
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
2 | www.annalsofsurgery.com C© 2014 Lippincott Williams & Wilkins
Annals of Surgery  Volume 00, Number 00, 2014 Discontinuation of Surgical Trials
2 hypotheses: trial discontinuation due to slow recruitment is (1)
less likely with industry-sponsored trials than with trials sponsored
by an academic investigator, due to differences in the amount of fi-
nancial and organizational resources between industry and academic
sponsors; and (2) less likely with adverse events being the primary
outcome than with efficacy outcomes only, due to more patient and
health care provider preference for 1 treatment arm in the latter case
hampering recruitment.
Using a multivariable hierarchical logistic regression model,
we examined the following prespecified predictors for nonjour-
nal publication of RCTs: “industry-sponsorship (vs investigator-
sponsorship),” “primary outcome being an adverse event (yes vs no),”
and “trial discontinuation for any reason (yes vs no).” We hypothe-
sized (1) that nonpublication was more likely in industry-sponsored
trials, as suggested by previous literature9; (2) that trial nonpublica-
tion was more likely in discontinued trials (assuming that only few
trials were discontinued because of compelling evidence of treatment
benefit or harm); and (3) that trial nonpublication was more likely
with adverse events being the primary outcome than with efficacy
outcomes only, due to the high interest in efficacy outcomes. We ac-
counted for clustering by the approving REC using a random effect
estimator.
We conducted 2 sensitivity analyses. First, we conducted the
multivariable analyses disregarding the clustering by the approving
REC. Second, we used multiple imputation to replace missing data
for independent and dependent variables.10
We conducted 1 posthoc analysis: Because trial comparisons
(surgical vs medical) refer to the a priori defined clinical areas and
not to study interventions, we compared trials with invasive inter-
ventions versus trials without invasive interventions using descrip-
tive analyses (Supplemental Digital Content Figure S1, available
at http://links.lww.com/SLA/A586). Analyses were conducted using
Stata Version 12.1 (StataCorp LP, College Station, TX).
RESULTS
Baseline Characteristics of Included Studies
We identified 863 protocols for RCTs involving 680,019
adult patients; 127 RCTs in the field of surgery (15%) and 736
in medicine (85%) (Fig. 1). We excluded 39 (5%) trials that were
never started and 8 (1%) that were still recruiting. A total of 816
trials (95%) involving 666,760 adult patients remained for the eval-
uation of completion and publication status [surgery: 115 (14%),
medicine: 701 (86%); Fig. 1]. The specialties contributing to at
least 10% of the trials were anesthesiology (13%), cardiothoracic
surgery (13%), obstetrics/gynecology (16%), ophthalmology (14%),
and orthopedics (10%) in surgical trials (Supplemental Digital Con-
tent Table S1a, available at http://links.lww.com/SLA/A585) and on-
cology (21%), cardiovascular (15%), and infectious diseases (11%)
in medical trials (Supplemental Digital Content Table S1b, available
at http://links.lww.com/SLA/A585). Table 1 presents an overview of
RCT characteristics by clinical area.
TABLE 1. Baseline Characteristics by Clinical Area
Clinical Area
Surgery Medicine
Characteristic 127 (100%) 736 (100%)
Intervention, n (%)
Medication 85 (67) 618 (84)
Invasive procedure 31 (24) 25 (3)
Rehabilitation 2 (2) 14 (2)
Behavioral 0 (0) 18 (3)
Diagnostic test 1 (1) 14 (2)
Other 8 (6) 47 (6)
Sample size,∗ median (IQR) 150 (60, 450) 288 (105, 628)
Industry funding, n (%)
Yes 76 (60) 552 (75)
No 51 (40) 184 (25)
Trial sponsor, n (%)
Industry 59 (46) 470 (64)
Academic investigator 71 (56) 276 (38)
Center status,† n (%)
Single center 50 (40) 99 (14)
Multicenter 75 (60) 633 (86)
Planned interim analysis, n (%)
Yes 30 (24) 249 (34)
No 97 (76) 487 (66)
Presence of DSMB, n (%)
Yes 24 (19) 223 (30)
No 103 (81) 513 (70)
Planned stopping rule, n (%)
Yes 10 (8) 142 (19)
No 117 (92) 594 (81)
In categorical variables, numbers (column percentages) are displayed.
∗Surgery: 4 missings; Medicine: 5 missings.
†Surgery: 2 missings, Medicine: 4 missings.
DSMB indicates Data and Safety Monitoring Board; IQR, interquartile range.
FIGURE 1. Flow chart of included studies: Studies eligible for assessment of discontinuation and of nonpublication, respectively.
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Discontinuation of Trials
We excluded 66 trials (12 surgical, 54 medical) with unclear
completion status (Fig. 1). In the remaining 750 trials (103 surgi-
cal, 647 medical), the overall proportion of discontinued trials was
43% (44/103) in surgical trials and 27% (176/647) in medical tri-
als with a risk difference of 16% (95% CI: 5%–26%; P = 0.001;
Table 2).
Reasons for RCT discontinuation by clinical area are presented
in Table 3. Slow recruitment was the most frequent reason for discon-
tinuation in both surgical (19/44, 43%) and medical (68/176, 39%)
trials. Stopping for slow recruitment was more frequent in surgical
than in medical trials [19/103 (18%) vs 68/647 (11%), risk difference
8%, 95% CI: 0.1%–16%; P = 0.020].
Results of our exploratory analysis comparing invasive with
noninvasive trials suggested that RCTs with invasive interventions
were more often discontinued for slow recruitment than RCTs with
noninvasive interventions (Supplemental Digital Content Figure S1,
available at http://links.lww.com/SLA/A586).
Publication of Trials
No trials had to be excluded for unclear publication status
(Fig. 1). The overall percentage of trials not published in any format
was 40% (46/115) among surgical trials and 34% (235/701) among
medical trials with a risk difference of 6% (95% CI: −3% to 16%;
P = 0.176; Table 2). Most trials were published as full journal arti-
cles [surgical 64/115 (56%), medical 421/701 (60%)] as opposed to
abstracts, letters, or other short forms of publication [surgical 5/115
(4%), medical 45/701 (6%)]. The overall percentage of trials not pub-
lished as full journal article was 44% (51/115) among surgical trials
and 40% (280/701) among medical trials with a risk difference of 4%
(95% CI: −5% to 14%; P = 0.373).
Of completed surgical trials 76% (45/59) and of completed
medical trials 79% (371/471) were published in any format. Of dis-
continued surgical trials 55% (24/44) and of discontinued medical
trials 52% (92/176) were published.
Results of the supplementary exploratory analysis comparing
invasive to noninvasive trials suggested no relevant differences in
publication rates (Supplemental Digital Content Figure S1, available
at http://links.lww.com/SLA/A586).
TABLE 2. Trial Completion and Publication Status by Clinical
Area
Clinical Area
Surgery Medicine
115 (100) 701 (100)
Completion status
Completed 59 (51) 471 (67)
Discontinued 44 (38) 176 (25)
Unclear 12 (11) 54 (8)
Publication status
Published 69 (60) 466 (66)
Abstract 5 (4) 31 (4)
Journal 64 (56) 421 (60)
Letter 0 (0) 7 (1)
Other 0 (0) 7 (1)
Not published 46 (40) 235 (34)
Numbers (column percentages) are displayed. Exclusion of never started trials
(surgery 10/127, 8%; medicine 29/736, 4%) and of still recruiting trials (surgery 2/127,
2%; medicine 6/736, 1%).
TABLE 3. Reasons for Discontinuation by Clinical Area
Clinical Area
Surgery Medicine
Reason 44 (100) 76 (100)
Benefit 1 (2) 6 (3)
Futility 5 (12) 28 (16)
Harm 4 (9) 17 (10)
Slow recruitment 19 (43) 68 (39)
External evidence 1 (2) 7 (4)
Lack of funding 0 (0) 4 (2)
Administrative 7 (16) 27 (15)
Other 0 (0) 7 (4)
Unclear 7 (16) 12 (7)
Numbers of studies (column percentages) are displayed.
Risk Factors for Surgical Trial Discontinuation Due to
Slow Recruitment
Study discontinuation due to slow recruitment was neither in-
fluenced by the type of sponsor [industry vs academic investigator,
adjusted odds ratio (OR) = 0.60, 95% CI: 0.20–1.85, P = 0.377
(Table 4)] nor by the type of primary outcome (ie, efficacy or harm)
(adjusted OR = 0.51, 95% CI: 0.14–1.85, P = 0.302). Sensitivity
analyses did not affect these findings (Supplemental Digital Content
Table S2, available at http://links.lww.com/SLA/A585).
Risk Factors for Nonpublication of Surgical Trials as
Full Journal Article
In multivariable analysis, trials discontinued for any reason
were significantly more likely to remain unpublished than completed
trials (adjusted OR = 4.18, 95% CI: 1.45–12.06,P= 0.008) (Table 5).
Industry-sponsored trials were significantly more likely to remain un-
published than trials sponsored by an academic investigator (adjusted
OR = 2.99, 95% CI: 1.05–8.58, P = 0.041). Trials with a primary
harm outcome were less likely to remain unpublished than trials with
primary efficacy outcomes only (adjusted OR = 0.28, 95% CI: 0.09–
0.92, P = 0.035).
Sensitivity analyses did not affect these findings with the
exception of the effect of the sponsor, which did not remain
statistically significant in the model with multiple imputations
(Supplemental Digital Content Table S3, available at http://links.
lww.com/SLA/A585).
DISCUSSION
This study suggests that the discontinuation rate is substantial
in surgical RCTs and that discontinuation is more frequent in surgical
than in medical RCTs. This applies to discontinuation for any reason
as well as to discontinuation for slow recruitment, which is the pre-
dominant reason for discontinuation. Trial discontinuation was found
to be a strong predictor for nonpublication.
Relation to Other Studies Investigating Trial
Discontinuation
Slow recruitment is an important problem in clinical trials. In
a cohort of 114 publicly funded multicenter trials, only 31% reached
their initial recruitment target, an additional 24% reached 80% of
their recruitment target and 53% of the trials were extended.11 The
target recruitment size was revised in 34% of trials, of which 86%
downward.11 Slow recruitment may occur because of a variety of
reasons, such as organizational failure, inadequate funding, or unre-
alistic projections regarding the number of eligible participants.12 It
may lead to longer study duration and increased resource consumption
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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TABLE 4. Univariable and Multivariable Logistic Regression for Trial Discontinuation of Surgical Trials for Slow
Recruitment (Using a Random Effect Estimator to Account for Clustering by the Approving Research Ethics
Committee)
Univariable Multivariable
Potential Predictor OR 95% CI P OR 95% CI P
Industry sponsor, yes vs no 0.66 0.22–1.97 0.457 0.60 0.20–1.85 0.377
Primary harm outcome, yes vs no 0.55 0.15–1.96 0.354 0.51 0.14–1.85 0.302
Of 115 trials, 12 had an unclear completion status and 14 had at least 1 missing covariate. Of the remaining 89 trials, included in the regression analysis, 19
were discontinued and 70 completed or discontinued for other reasons.
TABLE 5. Univariable and Multivariable Logistic Regression for Nonpublication as Full Journal Article of Surgical
Trials (Using a Random Effect Estimator to Account for Clustering by the Approving Research Ethics Committee)
Univariable Multivariable
Potential Predictor OR 95% CI P OR 95% CI P
Industry sponsor, yes vs no 2.02 0.84–4.88 0.119 2.99 1.05–8.58 0.041
Primary harm outcome, yes vs no 0.32 0.11–0.96 0.043 0.28 0.09–0.92 0.035
Trial discontinuation for any reason, yes vs no 2.26 0.94–5.44 0.068 4.18 1.45–12.06 0.008
Out of 115 trials, 26 had at least 1 missing covariate. Of the remaining 89 trials included in the regression analysis, 56 trials were published as full journal article
and 33 not published as full journal article.
and early trial discontinuation with less precise study findings.13 In
a Cochrane review investigating methods to improve recruitment, a
number of promising strategies have been described, such as tele-
phone reminders and opt-out policies.13 Most importantly, pilot stud-
ies may allow to estimate eligibility and consent rates more precisely
and thus should be considered when planning a RCT.14
Our exploratory analysis showed that trials with invasive in-
terventions tended to be more frequently discontinued for any reason
and were significantly more often discontinued for slow recruitment.
This result suggests that the type of intervention (invasive vs non-
invasive) rather than the setting (surgery vs medicine) represents a
barrier to successful recruitment.1
We found trial discontinuation to be more frequent in surgical
than in medical trials, both overall and for slow recruitment. Potential
explanations may be surgery-specific aspects and challenges with
clinical trials such as requirements concerning surgeon experience,
standardization of the intervention, and recruitment (eg, due to patient
or caregiver preference).1–3 In addition, there are some fundamental
differences concerning the premarket review and approval process of
devices versus drugs. Whereas for US Food and Drug Administration
approval, safety and efficacy have to be demonstrated in humans for
all drugs, this is only required for high-risk devices.15 Similarly in
Europe, clinical data are not required for lower risk devices.16 Thus,
depending on the risk class of surgical devices, regulatory approval
may not be based on clinical evidence, which potentially impacts
resource investment and other efforts to achieve trial completion.
Relation to Other Studies Investigating Trial
Nonpublication
In this study, 60% of surgical and 66% of medical trials were
published in any format and 56% and 60%, respectively, as full jour-
nal articles. These proportions are slightly higher than a previous
investigation of study protocols submitted to a Swiss REC with 52%
of trials getting published (233/451).9 In this previous Swiss study,
the odds for publication was higher with noncommercial funding,
which is in line with our results, higher with multicenter trials, in-
ternational collaboration, and a high sample size as assessed by me-
dian split.9 This investigation comprised, however, mostly medical
specialties and thus is not strictly comparable to the surgical trials
evaluated in our sample. In a Cochrane review of 79 studies investi-
gating the subsequent publication of abstracts presented at meetings,
the weighted full publication rate was 44.5% (95% CI: 43.9–45.1)
and an estimated cumulative publication rate after 9 years was 52.6%
overall and 63.1% for RCTs or controlled clinical trials.17 Abstract
acceptance for presentation at a meeting was found to be associated
with subsequent publication with an OR of 1.78 (95% CI: 1.50–
2.12).17
We found trial discontinuation to be an independent risk factor
for nonpublication. This may be explained by the fact that the most
frequent reasons of discontinuation of surgical RCTs were slow re-
cruitment, futility, or administrative reasons. These trials were thus
potentially more difficult to publish than the few trials stopped early
for benefit. Generally, in trials stopped early for benefit, treatment
effects tend to be large,18,19 increasing the chance of a trial to be
published. This is supported by a review of such trials in which the
majority of RCTs (92/143) were published in 5 high-impact medical
journals.19
Strengths and Limitations
The collaborating RECs granted us unrestricted access to trial
protocols. As outlined previously,20 this reduced the risk of selec-
tion bias; asking trialists or sponsors for permission would almost
certainly have led to oversampling of successfully completed and
published trials. However, some investigators may not have provided
useful information about reasons for trial discontinuation. In addi-
tion, our approach allowed us to collect more detailed information
about trial characteristics than investigations relying on trial registry
entries only.21 Moreover, we obtained study protocols from several
RECs in 3 countries, increasing the generalizability of our findings.4
In addition, our data extractions were based on a priori definitions7
and validated through regular quality assessments. Finally, our sen-
sitivity analyses support the robustness of the conducted statistical
analyses.
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Our investigation has some limitations. Although we included
a large number of approved RCTs, we were unable to adjust for
additional confounders because of the low number of surgical trials
and outcome events.8 We thus refrained from adjusting for trial
characteristics such as sample size and center status (single center vs
multicenter).
Implication for Daily Practice and Further Research
These findings of our study raise ethical concerns, as many
patients who consent to enroll in surgical trials do not contribute
to scientific knowledge, and suggest that considerable resources are
being wasted. Thus, our findings may have the following implications
during the different phases of a research pathway:
1. Trial conception and design. Strategies to prevent discontinuation
should be adopted already during the trial design phase, including
training in research methodology, realistic resource estimation (eg,
time of personnel), creating research infrastructures, and working
in networks and interdisciplinary teams involving trial methodolo-
gists, statisticians, data managers, and trial managers. Pilot studies
either as part of the trial (internal pilot) or stand-alone (external
pilot),14 that is, a small version of the full-scale study or feasibility
studies, are effective means to evaluate particular aspects such as
recruitment, resource utilization, and protocol feasibility.22 This
especially applies to trials involving surgical interventions, where
recruitment may be more challenging due to patient preferences.
Moreover, pilot studies may identify other challenges such as feasi-
bility of standardization of the surgical interventions. Pilot studies
should thus be considered when allocating sparse resources to
surgical RCTs. In addition, trials should be registered before en-
rolment of the first patient. This enhances transparency regarding
the targeted sample size and additionally allows identifying the
study while ongoing or after close-up before publication.
2. Trial conduct. Recruitment should be closely monitored and early
modification of trial methods foreseen to enhance recruitment if
necessary. The decision to discontinue a trial should be made
by an independent Data and Safety Monitoring Board based on
predefined criteria.
3. Trial reporting. Reasons for discontinuation and results of discon-
tinued RCTs should be transparently communicated and thus made
publicly available.
4. Health care decision making. When interpreting surgical litera-
ture, be it primary studies or systematic reviews, potential biases
introduced by discontinued RCTs or by nonpublication of trials
need to be considered.
CONCLUSIONS
More than 1 in 3 surgical RCTs is discontinued. Discontin-
uation is more frequent among surgical than among medical RCTs.
Slow recruitment is the predominant reason for early termination. Fur-
thermore, results from discontinued trials are more likely to remain
unpublished. Rigorous planning within a multidisciplinary research
framework, supported by pilot and feasibility studies, predefined cri-
teria for stopping a trial, applied by independent boards, and trans-
parent communication with stakeholders of surgical research and the
public could help achieve the ultimate goal of high-quality research
that improves the evidence base of surgical interventions.
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